Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

CD22 is a cell-surface adhesion molecule on most B-cell NHL, so it is a promising target for immunotherapy. HB22.7 is an anti-CD22 mAb that binds the two NH(2)-terminal immunoglobulin domains and specifically blocks the interaction of CD22 with its ligand. CD22-blocking mAbs induce apoptosis in neop...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Donnell, Robert T., Ma, Yunpeng, McKnight, Hayes C., Pearson, David, Tuscano, Joseph M.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2009
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749165/
https://www.ncbi.nlm.nih.gov/pubmed/19437017
http://dx.doi.org/10.1007/s00262-009-0713-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749165/
https://www.ncbi.nlm.nih.gov/pubmed/19437017
http://dx.doi.org/10.1007/s00262-009-0713-8

Ejemplares similares